Theraclone Sciences is a Seattle-based biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The Company's I-STAR™ technology harnesses the power of the human immune system to identify rare, naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Theraclone has established discovery partnerships with Pfizer, Zenyaku Kogyo and the International AIDS Vaccine Research Initiative.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/25/13 | $8,000,000 | Series B |
Alexandria Real Estate Equities Amgen Business Development ARCH Venture Partners Canaan Partners Healthcare Ventures MidCap Financial MPM Capital Silicon Valley Bank Versant Ventures Zenyaku Kogyo | undisclosed |
| 03/25/13 | $6,000,000 | Venture Debt |
